I am now part of a Washing ton Post panel of health care analysts. Each Monday, the Post sends us a question, and asks us to comment. This week, the question focused on “the pharmaceutical industry’s offer to has put $80 billion on the table to reduce the cost of health-care reform over the next decade. What is your reaction to the offer and the impact it will have on the debate?”
Below, my reply:
The announcement that drug-makers will offer 50% discounts to Medicare beneficiaries who fall into the Medicare Part D doughnut hole is excellent news for seniors. Drug-makers will help to bridge the gap in coverage that forces roughly 15% of seniors stop buying medications when their annual prescription drug bill reaches $2700.
But this is, as the president said, “a first step.” Pharma is going to have to do more.
Look at it this way: this year, prescription drug sales in the U.S. will total $252 billion.Meanwhile, if sales continue to rise—and drug-makers continue to hike prices, spending on drugs is expected to double between 2014 and 2018. By 2019, Pharma hopes to rake in over $500 billion in U.S. sales.
In that context, giving up $80 billion over ten years is not a huge sacrifice. Pretend that the $80 billion is spread out evenly, $8 billion a year. This means that in 2019, instead of showing revenues of $500 billion, the industry would have to make do with $492 billion. But unless GDP doubles, we cannot afford to spend $492 billion on drugs in 2019.
Why does Pharma charge U.S patients sky-high prices? Because it can. No one is pushing back. In other countries governments negotiate to protect dying patients from being gouged.
Meanwhile, Pharma is spending twice as much on marketing and advertising as it does on research. Perhaps it should re-think that spending—and pricing. Either that, or prepare to negotiate. Together, Medicare and a public sector insurer should be able to make drugs as affordable here as they are in France.